Uppsala, September 7, 2022. The European Commission has selected Dicot from thousands of small and medium-sized European companies as one of the companies to participate in the Innovation Radar Prize 2022.
Dicot's goal is to drastically change the way of treating erectile dysfunction by developing a new modern potency drug. The company has been noticed by the European Commission, which recently contacted and invited the company to participate in the Innovation Radar Prize 2022. Dicot is thus one of the companies selected in competition with thousands of EU-funded small and medium-sized enterprises.
The Innovation Radar is the European Commission's initiative to highlight EU-funded research and innovation projects with high potential. The goal is to make it easier for citizens, public officials, investors and corporates to identify successful businesses that have been supported by the EU. The companies are thereby given the opportunity to follow in the footsteps of previously funded companies, such as Skype, TomTom and BioNTech.
Within the framework of the initiative, the annual Innovation Radar Prize has been awarded since 2015, where the winners, among other things, get extensive exposure to European investors. The jury consists of renowned entrepreneurs, investors and start-up accelerators.
"It is very encouraging that we have been asked to participate in this competition. In addition to the honour, it is a welcome element in our work to establish Dicot internationally and get attention for what we do", says Elin Trampe, CEO of Dicot.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.